Predicting On-Target, Off-Tumor Toxicity of TCE's

Applied BioMath Assess can be used to optimize the design of CD3 bispecific T-cell engagers for the treatment of solid tumors by evaluating the risk of on-target, off-tumor toxicities through early predictions of therapeutic index (TI) and projections of effective and tolerable doses. In this case study, we demonstrate the ability to predict the on-target, off-tumor toxicity observed for solitomab, a drug that failed to meet its end points due to dose-limiting toxicity. We will use the Assess cell engager model pack to identify properties of tumor-associated antigens that could be more successfully targeted with a TCE. Furthermore, we will explore the feasibility of next-generation T-cell engager molecules to enhance tissue selectivity leading to improved therapeutic index.

Supplementary information, referenced in the case study, can be downloaded here.